The Impact of Loading Dose on Outcome in Stroke Patients Receiving Low-Dose Tissue Plasminogen Activator Thrombolytic Therapy

References

• HaleyEC, LevyDE, BrottTG, et al. Urgent therapy for stroke: part II. pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke. 1992;23(5):641–645. doi:10.1161/01.STR.23.5.6411579959
   PubMed Web of Science ®Google Scholar
• AdamsHP, BrottTG, FurlanAJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a special writing group of the stroke council, American Heart Association. Stroke. 1996;27(9):1711–1718.8784157
   PubMed Web of Science ®Google Scholar
• OngCT, SungSF, WuCS, et al. Early neurological improvement after intravenous tissue plasminogen activator infusion in patients with ischemic stroke aged 80 years or older. J Chin Med Assoc. 2014;77(4):179–183. doi:10.1016/j.jcma.2014.02.00224657175
   PubMed Web of Science ®Google Scholar
• HackeW, KasteM, FieschiC, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). second European-Australasian acute stroke study investigators. Lancet. 1998;352(9136):1245–1251. doi:10.1016/S0140-6736(98)08020-99788453
   PubMed Web of Science ®Google Scholar
• ChaoAC, HsuH-Y, ChungC-P, et al. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study. Stroke. 2010;41(5):885–890. doi:10.1161/STROKEAHA.109.57560520224056
   PubMed Web of Science ®Google Scholar
• RaoNM, LevineSR, GornbeinJA, SaverJL. Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the national institute of neurological disorders and stroke tissue-type plasminogen activator trials. Stroke. 2014;45(9):2728–2733. doi:10.1161/STROKEAHA.114.00513525096731
   PubMed Web of Science ®Google Scholar
• MazyaMV, LeesKR, CollasD, et al. IV thrombolysis in very severe and severe ischemic stroke: results from the SITS-ISTR registry. Neurology. 2015;85(24):2098–2106. doi:10.1212/WNL.000000000000219926546630
   PubMed Web of Science ®Google Scholar
• YamaguchiT, MoriE, MinematsuK, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006;37(7):1810–1815. doi:10.1161/01.STR.0000227191.01792.e316763187
   PubMed Web of Science ®Google Scholar
• ToyodaK, KogaM, NaganumaM, et al. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register. Stroke. 2009;40(11):3591–3595. doi:10.1161/STROKEAHA.109.56299119762694
   PubMed Web of Science ®Google Scholar
• MiyagiT, KogaM, ShiokawaY, et al. Intravenous alteplase at 0.6 mg/kg for acute stroke patients with basilar artery occlusion: the stroke acute management with urgent risk factor assessment and improvement (SAMURAI) recombinant tissue plasminogen activator registry. J Stroke Cerebrovasc Dis. 2013;22(7):1098–1106. doi:10.1016/j.jstrokecerebrovasdis.2012.08.01323063059
   PubMed Web of Science ®Google Scholar
• ChenH, ZhuG, LiuN, ZhangW. Low-dose tissue plasminogen activator is as effective as standard tissue plasminogen activator administration for the treatment of acute ischemic stroke. Curr Neurovasc Res. 2014;11(1):62–67. doi:10.2174/156720261066613112615004324279381
   PubMed Web of Science ®Google Scholar
• KimBJ, HanM-K, ParkTH, et al. Low-versus standard-dose alteplase for ischemic strokes within 4.5 hours: a comparative effectiveness and safety study. Stroke. 2015;46(9):2541–2548. doi:10.1161/STROKEAHA.115.01018026243232
   PubMed Web of Science ®Google Scholar
• OngCT, WongYS, WuCS, SuYH. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator. Drug Des Devel Ther. 2017;11:1559–1566. doi:10.2147/DDDT.S133759
   PubMed Web of Science ®Google Scholar
• LiuMD, NingWD, WangRC, et al. Low-dose versus standard-dose tissue plasminogen activator in acute ischemic stroke in Asian populations: a meta-analysis. Medicine. 2015;94(52):e2412. doi:10.1097/MD.000000000000241226717400
   PubMed Web of Science ®Google Scholar
• RamaiahSS, YanB. Low-dose tissue plasminogen activator and standard-dose tissue plasminogen activator in acute ischemic stroke in Asian populations: a review. Cerebrovasc Dis. 2013;36(3):161–166. doi:10.1159/00035416224135524
   PubMed Web of Science ®Google Scholar
• DharmasarojaPA, PattaraarchachaiJ. Low vs standard dose of recombinant tissue plasminogen activator in treating East Asian patients with acute ischemic stroke. Neurol India. 2011;59(2):180–184. doi:10.4103/0028-3886.7913221483113
   PubMed Web of Science ®Google Scholar
• LiaoX, WangY, PanY, et al. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses. Stroke. 2014;45(8):2354–2358. doi:10.1161/STROKEAHA.114.00598925013020
   PubMed Web of Science ®Google Scholar
• AndersonCS, RobinsonT, LindleyRI, et al. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med. 2016;374(24):2313–2323. doi:10.1056/NEJMoa151551027161018
   PubMed Web of Science ®Google Scholar
• MerinoJG, LatourLLP, AnLP, HsiaAW, KangD-W, WarachS. Reperfusion half-life: a novel pharmacodynamic measure of thrombolytic activity. Stroke. 2008;39(7):2148–2150. doi:10.1161/STROKEAHA.107.51081818451344
   PubMed Web of Science ®Google Scholar
• ChangYJ, RyuSJ, ChenJR, HuHH, YipPK, ChiuTF. Guidelines for the general management of patients with acute ischemic stroke. Acta Neurol Taiwan. 2008;17(4):275–294.19280874
   PubMedGoogle Scholar
• SpartanoNLP, BernhardtJP. Prestroke physical activity to reduce stroke severity: moving to lower risk with light activity. Neurology. 2018;91(16):727–728. doi:10.1212/WNL.000000000000634230232247
   PubMed Web of Science ®Google Scholar
• ChaoAC, LiuC-K, ChenC-H, et al. Different doses of recombinant tissue-type plasminogen activator for acute stroke in Chinese patients. Stroke. 2014;45(8):2359–2365. doi:10.1161/STROKEAHA.114.00524524994721
   PubMed Web of Science ®Google Scholar
• MehtaRH, CoxM, SmithEE, et al. Race/ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy. Stroke. 2014;45(8):2263–2269. doi:10.1161/STROKEAHA.114.00501925070958
   PubMed Web of Science ®Google Scholar
• MoriE, MinematsuK, NakagawaraJ, YamaguchiT. Factors predicting outcome in stroke patients treated with 0.6 mg/kg alteplase: evidence from the Japan Alteplase Clinical Trial (J-ACT). J Stroke Cerebro. 2011;20(6):517–522.
   PubMed Web of Science ®Google Scholar